August 21, 2022
1 min read

FDA asks Pfizer to test second Paxlovid course

The regulator said a formal plan for the clinical trial is expected to be finalized this month…reports Asian Lite News

The US Food and Drug Administration (FDA) has ordered Pfizer Inc. to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.

The drugmaker must produce initial results of a randomized controlled trial of a second course of the antiviral by Sept. 30 next year, the FDA told Pfizer in a letter dated Aug. 5.

The regulator said a formal plan for the clinical trial is expected to be finalized this month.

Pfizer is “working with the FDA to finalize a protocol to study patients who may be in need of retreatment,” and will provide details when available, a company spokesperson said.

ALSO READ: Daesh militant gets life in US prison  

Previous Story

Daesh militant gets life in US prison  

Next Story

Commemorating 30 years of Israel, India diplomatic relations

Latest from -Top News

Financial Turmoil Grips Bangladesh

The crisis emerged with the political transition after the ouster of former Prime Minister Sheikh Hasina following a violent uprising last year….reports Asian Lite News Bangladesh is grappling with an economic crisis

Hamas Meets Turkish FM Over Gaza Crisis

The delegation briefed Hakan on the latest developments regarding the ceasefire in the Gaza Strip and the delegation’s recent visit to Cairo….reports Asian Lite News A Hamas delegation met with Turkish Foreign

India, France Set to Seal Rafale Deal

Estimated cost of this deal is valued at around Rs 63,000 crore…reports Asian Lite News India and France will on Monday sign the deal for 26 Rafale fighter jets for the Indian
Go toTop

Don't Miss

Delhi hosts Quad Policy Planners’ meet

Quad is notably a diplomatic partnership between Australia, India, Japan,

20 years later, Senate eyes repeal of Iraq war authorization

The vote, which would come after consideration in the Senate